Max Healthcare Institute Limited — PPTs, 07-02-2026: Investor Presentation

Max Healthcare shows robust business performance, with net revenue for the financial results for the nine months ended December growing 19% year-on-year to ₹7,524 Cr. Profit after tax saw a 30% jump to ₹1,244 Cr, while operating EBITDA rose 16% to ₹1,956 Cr, maintaining a healthy 26% margin. The company's strong presence in key metros like Delhi NCR and Mumbai continues to drive growth, reflected in an ARPOB of ₹78,000 and ~76% occupancy. ROCE for the period was ~26%.

Key growth strategies involve a significant capacity expansion plan, aiming to add approximately 4,600 beds in the next 3-4 years through brownfield, greenfield, and asset-light models, effectively doubling its current bed capacity. Recent developments include operationalizing Mohali Tower 2 (160 beds) and Nanavati-Max Tower 2 (Phase 1, 280 beds, 63 now live), plus Max Smart Saket awaiting operational clearance for 200 new beds. The company is also leveraging digital platforms like 'Max MyHealth' and expanding capital-light adjacencies such as Max Lab and Max@Home. Management remains focused on clinical excellence and long-term profitable growth.